The study is being carried out along with the NIH unit NIAID and the US BARDA. Credit: Ewa Urban from Pixabay.

Moderna has announced that the Phase III COVE study of mRNA-1273, its vaccine candidate against Covid-19, met the statistical criteria pre-specified in the study protocol, with a vaccine efficacy of 94.5%.

The independent, UK National Institute of Health (NIH)-appointed Data Safety Monitoring Board (DSMB) confirmed the efficacy data.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

mRNA-1273 is a vaccine against Covid-19 encoding for a prefusion stabilised form of the Spike (S) protein.

The study is being carried out along with the NIH unit National Institute of Allergy and Infectious Diseases (NIAID) and the US Biomedical Advanced Research and Development Authority (BARDA).

The randomised, 1:1, placebo-controlled trial enrolled over 30,000 adult participants in the US. They were administered a 100µg dose of mRNA-1273 or placebo.

Its primary endpoint is the prevention of symptomatic Covid-19 disease, while key secondary endpoints include the prevention of severe disease and infection.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

This first interim analysis was based on 95 cases, of which 90 cases were observed in the placebo group versus five in mRNA-1273 group, resulting in a point estimate of vaccine efficacy of 94.5%.

A secondary endpoint analysed 11 severe cases of Covid-19 in this first interim analysis. Data showed that all cases occurred in the placebo group.

As per the preliminary analysis, the vaccine has consistent safety and efficacy profile across all evaluated subgroups.

Moderna CEO Stéphane Bancel said: “This positive interim analysis from our Phase III study has given us the first clinical validation that our vaccine can prevent Covid-19 disease, including severe disease.”

Moderna plans to apply for emergency use authorisation (EUA) with the US Food and Drug Administration (FDA) soon.

Last month, Moderna completed the enrolment of participants for the Phase III COVE study of mRNA-1273.

Clinical Trials Arena Excellence Awards - Nominations Closed

Nominations are now closed for the Clinical Trials Arena Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
Science 37 has won the Research and Development Award in the Site Innovation category for its FDA inspected Direct-to-Patient Site model, delivering nationwide access, faster enrollment and higher retention. Explore how its virtual-first, in home approach is reshaping trial operations and accelerating time to data-driven decisions..

Discover the Impact